UroGen Pharma URGN
NASDAQ URGN
$25.30 -0.81 (-3.08%)
As of: Nov 12, 2026 · 10:13 AM EST

UroGen Pharma (URGN) Return on Sales [ROS] (2017 - 2026)

Updated

UroGen Pharma's Return on Sales [ROS] came in at 0.15% for Q2 2026, up 171.32 percentage points from -171.17% a year earlier and up 39.92 percentage points from the prior quarter.

Analysis

UroGen Pharma (URGN) Return on Sales [ROS] (2017 - 2026) Analysis & Trends

Over the trailing twelve months to Jun 30, 2026, UroGen Pharma reported Return on Sales [ROS] of -35.32%, up 95.80 percentage points year-over-year; for FY2025, it came in at -113.73%, down 6.67 percentage points from FY2024.

  • Return on Sales [ROS] carries a five-year change of +960.42 percentage points (FY2020 to FY2025).
  • Going back by year, Return on Sales [ROS] was -107.06% in FY2024 (-27.83 pp), -79.23% in FY2023 (+43.58 pp), -122.82% in FY2022 (+69.29 pp) and -192.11% in FY2021 (+882.04 pp).
  • The Q2 2026 figure represents the highest quarterly Return on Sales [ROS] in data going back to Q1 2017.
  • Year-over-year, Return on Sales [ROS] has increased for three consecutive quarters, with an average year-over-year change of +24.05 percentage points over the last eight quarters.
  • The fastest year-over-year change in Return on Sales [ROS] over five years came in Q3 2021 (a gain of 634.99 percentage points), and the weakest in Q2 2025 (a drop of 52.90 percentage points).
  • Business Quant data shows URGN's Return on Sales [ROS] at -39.76% (Q1 2026), -50.52% (Q4 2025) and -99.65% (Q3 2025) in the three quarters before Q2 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 34.46%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 24.35%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 36.01%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 30.74%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 29.12%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 35.79%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 41.71%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 32.98%
10 UroGen Pharma 1.24 Bn 782.15 Mn 81.50 Mn 9.36%
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 9.36%
Jun 30, 2026 0.15%
Mar 31, 2026 -39.76%
Dec 31, 2025 -50.52%
Sep 30, 2025 -99.65%
Jun 30, 2025 -171.17%
Mar 31, 2025 -182.26%
Dec 31, 2024 -112.59%
Sep 30, 2024 -69.61%
Jun 30, 2024 -118.27%
Mar 31, 2024 -137.05%
Dec 31, 2023 -62.09%
Sep 30, 2023 -64.74%
Jun 30, 2023 -72.77%
Mar 31, 2023 -128.23%
Dec 31, 2022 -112.10%
Sep 30, 2022 -112.36%
Jun 30, 2022 -112.71%
Mar 31, 2022 -161.88%
Dec 31, 2021 -123.13%
API Access

UroGen Pharma Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=URGN&period=max&api_key=YOUR_API_KEY